Media coverage about Microbot Medical (NASDAQ:MBOT) has been trending somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Microbot Medical earned a coverage optimism score of 0.20 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 45.656371805834 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the news articles that may have effected Accern’s rankings:
- Biotech Sector Rises on Accelerated Anti-cancer Drug Candidate … – Markets Insider (markets.businessinsider.com)
- There Are Mixed Technical Signals in Microbot Medical Inc. (MBOT) – StockNewsGazette (stocknewsgazette.com)
- Investor Network: Microbot Medical Inc to Host Earnings Call (finance.yahoo.com)
- Microbot Medical Inc. Reports Second Quarter 2017 Financial Results and Recent Development and Strategic Progress (finance.yahoo.com)
- Microbot Medical Inc. (NASDAQ:MBOT) Issues Quarterly Earnings Results (americanbankingnews.com)
Microbot Medical (MBOT) traded down 3.60% during mid-day trading on Friday, hitting $1.07. 410,614 shares of the stock were exchanged. The firm’s market cap is $39.58 million. Microbot Medical has a 12-month low of $1.03 and a 12-month high of $18.18. The company has a 50 day moving average of $1.23 and a 200 day moving average of $3.71.
Microbot Medical (NASDAQ:MBOT) last announced its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.48) by $0.44. On average, equities analysts anticipate that Microbot Medical will post ($25.02) earnings per share for the current fiscal year.
Separately, ValuEngine raised shares of Microbot Medical from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd.
In other news, major shareholder Leon Lewkowicz sold 71,224 shares of the company’s stock in a transaction on Friday, June 16th. The stock was sold at an average price of $1.67, for a total value of $118,944.08. Following the completion of the sale, the insider now owns 3,078,214 shares in the company, valued at $5,140,617.38. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 1.30% of the company’s stock.
Microbot Medical Company Profile
Microbot Medical Inc, formerly StemCells, Inc, is a medical device company. The Company specializes in the researching, designing, developing and commercializing transformational micro-robotic medical technologies leveraging the artificial and natural lumens within the human body. It is engaged in developing its two product candidates: the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH), and TipCAT, a self-propelling, semi-disposable endoscope that the Company is developing for use in colonoscopy procedures.
Receive News & Ratings for Microbot Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.